Sivia Capital Partners LLC raised its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 47.4% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 5,171 shares of the company's stock after buying an additional 1,663 shares during the period. Sivia Capital Partners LLC's holdings in Johnson & Johnson were worth $858,000 as of its most recent filing with the SEC.
Several other hedge funds have also recently modified their holdings of the company. WealthTrak Capital Management LLC purchased a new stake in Johnson & Johnson in the 4th quarter worth approximately $26,000. Mountain Hill Investment Partners Corp. bought a new stake in shares of Johnson & Johnson in the 4th quarter worth approximately $29,000. Bay Harbor Wealth Management LLC purchased a new stake in shares of Johnson & Johnson in the fourth quarter worth $32,000. Conquis Financial LLC bought a new stake in Johnson & Johnson during the 4th quarter valued at about $33,000. Finally, Bernard Wealth Management Corp. purchased a new stake in Johnson & Johnson during the 4th quarter valued at $36,000. Institutional investors own 69.55% of the company's stock.
Johnson & Johnson Stock Down 0.8%
Shares of JNJ stock traded down $1.26 during mid-day trading on Wednesday, hitting $155.19. The stock had a trading volume of 4,232,394 shares, compared to its average volume of 7,935,665. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The firm's 50-day moving average is $153.52 and its two-hundred day moving average is $153.69. The firm has a market capitalization of $373.41 billion, a P/E ratio of 23.34, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.59 by $0.18. The firm had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. On average, analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.
Johnson & Johnson Increases Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were given a $1.30 dividend. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date was Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.35%. Johnson & Johnson's dividend payout ratio (DPR) is presently 57.84%.
Analyst Upgrades and Downgrades
JNJ has been the topic of a number of recent analyst reports. Morgan Stanley raised their price target on shares of Johnson & Johnson from $164.00 to $169.00 and gave the company an "equal weight" rating in a report on Wednesday, April 16th. Benchmark raised shares of Johnson & Johnson to a "strong-buy" rating in a research note on Thursday, April 24th. Royal Bank of Canada restated an "outperform" rating and issued a $181.00 price target on shares of Johnson & Johnson in a research note on Thursday, June 5th. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Finally, Wall Street Zen lowered shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 22nd. Eleven research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $170.88.
View Our Latest Stock Analysis on JNJ
About Johnson & Johnson
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Featured Articles
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
